ORIC® Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 2025
Oric Pharmaceuticals, Inc. (ORIC)
Company Research
Source: GlobeNewswire
Systemic activity of 35% ORR in 2L+ patients, including in patients with active brain metastases Manageable safety profile with low discontinuation rate Enrollment completed; no further development planned in this patient population Company to host a conference call and webcast on Saturday, December 6, 2025, at 8:00 pm ET SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced data from a Phase 1b trial of enozertinib (ORIC-114) at the ESMO Asia Congress 2025. Data in previously treated NSCLC patients with HER2 exon 20 mutations were presented at a poster session, and the poster can be found in the publication section of ORIC’s website here. Enozertinib Phase 1b Trial DesignEnozertinib is being evaluated in a Phase 1b trial in patients with locally advanced or metastatic NSCLC with HER2 e
Show less
Read more
Impact Snapshot
Event Time:
ORIC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ORIC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ORIC alerts
High impacting Oric Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ORIC
News
- Oric Pharmaceuticals (NASDAQ:ORIC) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $20.00 price target on the stock.MarketBeat
- ORIC® Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming MilestonesGlobeNewswire
- Oric Pharmaceuticals (NASDAQ:ORIC) was upgraded by analysts at Piper Sandler to a "strong-buy" rating.MarketBeat
- Oric Pharmaceuticals (NASDAQ:ORIC) is now covered by analysts at Piper Sandler. They set an "overweight" rating on the stock.MarketBeat
- ORIC® Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
ORIC
Earnings
- 11/13/25 - Beat
ORIC
Sec Filings
- 1/16/26 - Form 144
- 1/16/26 - Form 144
- 1/6/26 - Form 4
- ORIC's page on the SEC website